Febrile Neutropenia Market Report 2026

The febrile neutropenia market size has grown strongly in recent years. It will grow from $11.28 billion in 2025 to $11.99 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to growth in cancer chemotherapy usage, increased hospital admissions, availability of broad-spectrum antibiotics, improved infection awareness, expansion of oncology centers.

The febrile neutropenia market size is expected to see strong growth in the next few years. It will grow to $15.19 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to advancements in targeted antimicrobial therapy, growth in oncology patient population, improved early infection detection, rising use of G-CSFs, expansion of precision oncology care. Major trends in the forecast period include rising incidence of chemotherapy-induced neutropenia, increased use of empirical antibiotic therapy, growing adoption of supportive care treatments, expansion of hospital-based infection management, improved diagnostic and monitoring technologies.

The rising prevalence of cancer is expected to drive growth in the febrile neutropenia market in the coming years. Cancer is a complex group of diseases characterized by uncontrolled growth of abnormal cells that can invade surrounding tissues and spread to other parts of the body. The increasing incidence of cancer is influenced by factors such as an aging population, environmental and occupational exposures, genetic predisposition, and hormonal and reproductive factors. Febrile neutropenia plays a critical role in supporting cancer patients by highlighting the elevated risk of infections during chemotherapy, enabling early intervention and targeted treatments to prevent life-threatening complications, improve patient outcomes, and allow timely continuation of cancer therapy. For example, in 2024, the Canadian Cancer Society, a Canada-based national cancer charity, reported that 32,100 people were diagnosed with lung cancer in Canada, accounting for 23.5% of all cancer-related deaths. Notably, lung cancer cases among females increased from 15,800 in 2023 to 17,300 in 2024. Therefore, the rising cancer prevalence is fueling growth in the febrile neutropenia market.

Key companies in the febrile neutropenia market are focusing on developing advanced biosimilar drugs, such as long-acting granulocyte-colony stimulating factor (G-CSF) fusion proteins, to gain a competitive edge. These fusion G-CSFs are recombinant proteins that link G-CSF to an Fc fragment, allowing sustained neutrophil stimulation throughout a chemotherapy cycle. For instance, in November 2024, Evive Biotech, a Singapore-based biopharmaceutical company, launched in Germany a non-pegylated long-acting G-CSF for chemotherapy-induced neutropenia, providing an extended half-life via an IgG2-Fc fusion and mammalian cell expression for human-like glycosylation. These next-generation and biosimilar G-CSFs improve patient access and reduce dosing frequency, although they face regulatory complexities and potential immunogenicity concerns.

In July 2023, Assertio Holdings Inc., a US-based pharmaceutical company, acquired Spectrum Pharmaceuticals for an undisclosed sum. This acquisition aims to expand and diversify Assertio’s revenue base, strengthen its oncology portfolio with ROLVEDON (eflapegrastim-xnst) injection, and enhance its commercial and digital marketing capabilities. Spectrum Pharmaceuticals is a US-based pharmaceutical company that develops and manufactures drugs for febrile neutropenia.

Major companies operating in the febrile neutropenia market are Pfizer Inc., Sanofi S.A., Amgen Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Aurobindo Pharma Ltd., Lupin Limited, Hospira Inc., Coherus BioSciences Inc., Gennova Biopharmaceuticals Limited, Dr Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Bayer AG, Cipla Ltd., Zydus Cadila, Celltrion Inc., Samsung Bioepis Co. Ltd.

North America was the largest region in the febrile neutropenia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the febrile neutropenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the febrile neutropenia market by raising prices for imported antibiotics, antifungals, G-CSFs, and diagnostic consumables. Hospitals and oncology centers in Asia-Pacific and Europe are most affected due to global drug supply dependencies. These higher costs can delay infection management in vulnerable patients. However, tariffs are promoting local production of critical supportive-care medicines, strengthening long-term supply security.

The febrile neutropenia market research report is one of a series of new reports that provides febrile neutropenia market statistics, including febrile neutropenia industry global market size, regional shares, competitors with a febrile neutropenia market share, detailed febrile neutropenia market segments, market trends and opportunities, and any further data you may need to thrive in the febrile neutropenia industry. This febrile neutropenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Febrile neutropenia is a medical condition defined by a fever (100.4°F or higher) and a low neutrophil count, with neutrophils being a type of white blood cell critical for fighting infections. This condition commonly occurs in patients undergoing chemotherapy or other treatments that weaken the immune system, increasing their susceptibility to infections.

The main treatment approaches for febrile neutropenia include empirical antibiotic therapy, targeted antibiotic therapy, and supportive care. Empirical antibiotic therapy involves initiating treatment with broad-spectrum antibiotics based on clinical evaluation before the specific causative pathogen is identified. Risk factors include chemotherapy-induced neutropenia, transplant-related neutropenia, and genetic disorders, while possible causes involve gram-negative bacteria, gram-positive bacteria, fungal infections, and viral infections. Diagnosis is carried out using various methods such as blood cultures, imaging tests, and bone marrow aspiration.

The febrile neutropenia market consists of revenues earned by entities by providing services such as diagnostic services, hematologic support, hospitalization and monitoring, and outpatient management. The market value includes the value of related goods sold by the service provider or included within the service offering. The febrile neutropenia market also includes sales of antibiotics, antifungal and antiviral medications, urinalysis, and urine culture. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.